- Report
- October 2025
- 199 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- October 2025
- 198 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- October 2025
- 186 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- October 2025
- 191 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- October 2025
- 193 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- October 2025
- 194 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- October 2025
- 191 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- October 2025
- 184 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- October 2025
- 192 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- August 2025
- 182 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- August 2025
- 180 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- August 2025
- 188 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- August 2025
- 188 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- August 2025
- 181 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- August 2025
- 192 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- August 2025
- 186 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- August 2025
- 193 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- August 2025
- 197 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- August 2025
- 183 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP
- Report
- August 2025
- 187 Pages
Global
From €3134EUR$3,545USD£2,728GBP
€3482EUR$3,939USD£3,032GBP

The insulin market is a subset of the larger endocrine and metabolic disorders drugs market. Insulin is a hormone produced by the pancreas that helps regulate the body's blood sugar levels. It is used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use it effectively. Insulin is available in both short-acting and long-acting forms, and is typically administered via injection or an insulin pump.
The insulin market is highly competitive, with a number of major pharmaceutical companies offering a variety of insulin products. These include Eli Lilly, Novo Nordisk, Sanofi, and Merck. Additionally, there are a number of smaller companies that specialize in the production of insulin, such as Biocon, Wockhardt, and Wockhardt USA. Show Less Read more